Cisatracurium: Uses, Dosage, Side Effects & Warnings | DrugsAtlas
Authoritative Clinical Reference
Navigation
DRUG NAME: Cisatracurium
Therapeutic Class: Neuromuscular Blocking Agent
Subclass: Non-depolarising Benzylisoquinolinium Muscle Relaxant
Specialty: Anaesthesiology
Schedule (India): Schedule H
Route(s): Intravenous (IV)
Formulations Available in India:
- Cisatracurium besilate injection: 2 mg/mL in 5 mL ampoule (10 mg)
- Cisatracurium besilate injection: 2 mg/mL in 10 mL ampoule (20 mg)
- Cisatracurium besilate injection: 10 mg/mL in 5 mL vial (50 mg) — available in select tertiary care settings
INDICATIONS + DOSING — FOR CLINICIAN USE ONLY
Primary Indications (Approved / Standard in India)
▶️ Facilitation of Endotracheal Intubation
| Parameter | Details |
|
Starting dose
|
0.15–0.2 mg/kg IV bolus over 5–10 seconds |
|
Titration
|
Not applicable for intubation dose |
|
Usual maintenance dose
|
As per surgical relaxation dosing |
|
Maximum dose
|
Single intubating dose as stated |
|
Onset
|
2–3 minutes |
|
Duration of action
|
40–50 minutes |
Clinical Notes:
- Slower onset than succinylcholine; not ideal for rapid sequence intubation
- Adequate anaesthesia/sedation must be ensured before administration
- Higher doses (0.2 mg/kg) provide faster onset but similar duration
▶️ Skeletal Muscle Relaxation during Surgical Procedures
| Parameter | Details |
|
Starting dose
|
0.15–0.2 mg/kg IV bolus (after induction agent) |
|
Titration
|
Based on neuromuscular monitoring (train-of-four); adjust to surgical requirement |
|
Usual maintenance dose
|
0.03 mg/kg IV bolus every 20–30 minutes OR continuous infusion 1–2 mcg/kg/min |
|
Maximum dose
|
No fixed maximum; titrate to clinical response and neuromuscular monitoring |
Clinical Notes:
- No cumulative effect with repeated dosing — predictable recovery profile
- Use train-of-four (TOF) monitoring to optimize dosing
- Metabolism via Hofmann elimination (organ-independent) — unaffected by renal or hepatic dysfunction
▶️ Facilitation of Mechanical Ventilation in ICU
| Parameter | Details |
|
Starting dose
|
0.1–0.2 mg/kg IV loading bolus |
|
Titration
|
Based on TOF monitoring; target 1–2 twitches |
|
Usual maintenance dose
|
1–3 mcg/kg/min continuous IV infusion |
|
Maximum dose
|
Titrate to effect; no fixed ceiling |
|
Duration
|
Shortest effective duration; daily interruption recommended |
Clinical Notes:
- Preferred non-depolarising agent in ICU due to organ-independent metabolism
- Concurrent adequate sedation and analgesia mandatory (provides no sedation/analgesia)
- Higher infusion rates may be required in patients receiving corticosteroids
- Daily sedation/paralysis interruption to assess recovery and prevent prolonged weakness
Secondary Indications — Adults (Off-label, if any)
▶️ Facilitation of Controlled Ventilation in Severe ARDS or Refractory Status Asthmaticus
- Indication: Neuromuscular blockade to optimize mechanical ventilation in severe respiratory failure
- Dose: As per ICU indication; loading 0.1–0.2 mg/kg IV, then 1–3 mcg/kg/min infusion
- Duration: Limited to period of ventilatory requirement; typically 24–48 hours
- OFF-LABEL
- Specialist only — Critical care specialist supervision mandatory
- Evidence basis: ACURASYS trial (ARDS); Indian critical care practice; ISCCM protocols
PAEDIATRIC DOSING (Specialist Only)
Primary Indications (Approved / Standard in India)
▶️ Muscle Relaxation for Intubation and Surgical Anaesthesia
| Age Group | Starting Dose | Maintenance Dose | Clinical Notes |
|
Infants (1–12 months)
|
0.15 mg/kg IV bolus | 0.03 mg/kg IV every 20–25 min OR 1–2 mcg/kg/min infusion | Response may be variable; close monitoring required |
|
Children (1–12 years)
|
0.1–0.15 mg/kg IV bolus | 0.03 mg/kg IV every 20–30 min OR 1–2 mcg/kg/min infusion | May require slightly higher doses than adults |
|
Adolescents (>12 years)
|
0.15–0.2 mg/kg IV bolus | 0.03 mg/kg IV every 20–30 min OR 1–2 mcg/kg/min infusion | Adult dosing applies |
Safety Monitoring:
- Mandatory neuromuscular monitoring (train-of-four or peripheral nerve stimulator)
- Temperature monitoring (hypothermia prolongs action)
- Continuous SpO₂ and capnography monitoring
Minimum Age: Use in neonates (<1 month) only under paediatric anaesthesiologist or intensivist supervision due to limited data and variable pharmacokinetics.
Secondary Indications — Paediatrics (Off-label, if any)
▶️ ICU Paralysis for Mechanical Ventilation in PICU
- Indication: Facilitation of mechanical ventilation in paediatric ICU
- Dose: Loading 0.1–0.15 mg/kg IV; maintenance 1–2 mcg/kg/min infusion
- Duration: Shortest effective duration; daily interruption to assess recovery
- OFF-LABEL
- Specialist only — Paediatric intensivist supervision mandatory
- Evidence basis: Extrapolated from adult ICU practice; Indian PICU protocols
RENAL ADJUSTMENT
No dose adjustment required.
Rationale: Cisatracurium undergoes Hofmann elimination (spontaneous degradation at physiological pH and temperature) — completely organ-independent pathway. Safe in all degrees of renal impairment including dialysis patients. No accumulation of active drug or metabolites.
HEPATIC ADJUSTMENT
| Hepatic Function | Recommendation |
|
Mild impairment
|
No adjustment required |
|
Moderate impairment
|
No adjustment required |
|
Severe impairment
|
No adjustment required; Hofmann elimination is independent of hepatic function |
Note: Severe acidosis or hypothermia (which may accompany hepatic failure) can slow Hofmann elimination — monitor neuromuscular function closely in such patients.
CONTRAINDICATIONS
- Known hypersensitivity to cisatracurium besilate or other benzylisoquinolinium compounds
- History of anaphylaxis to any neuromuscular blocking agent
- Inability to provide adequate mechanical ventilation support
CAUTIONS
- Neuromuscular disorders (myasthenia gravis, Lambert-Eaton syndrome) — extreme sensitivity; reduce dose significantly
- Burns or prolonged immobilization — resistance may develop; higher doses often required due to receptor upregulation
- Electrolyte abnormalities (hypokalaemia, hypocalcaemia, hypermagnesaemia) — may potentiate blockade
- Acidosis — slows Hofmann elimination; prolonged action
- Hypothermia — significantly slows Hofmann degradation; expect prolonged effect
- Prolonged ICU use with concurrent corticosteroids — increased risk of ICU-acquired weakness/myopathy
- Elderly or cachectic patients — may have increased sensitivity
- Ensure reversal agents (neostigmine + glycopyrrolate) or sugammadex are available
PREGNANCY
| Parameter | Details |
|
Risk category
|
No formal Indian category; limited human data but generally considered safe for procedural use |
|
Use in pregnancy
|
May be used when general anaesthesia is required (e.g., caesarean section); minimal placental transfer |
|
Preferred alternatives
|
Succinylcholine preferred for rapid sequence induction in obstetric anaesthesia |
|
Monitoring
|
Monitor maternal ventilation; fetal heart rate monitoring; assess neonatal respiratory function at delivery |
LACTATION
| Parameter | Details |
|
Compatibility
|
Compatible with breastfeeding |
|
Drug levels in milk
|
Negligible; rapid degradation via Hofmann elimination and poor oral bioavailability |
|
Preferred alternatives
|
None required |
|
Infant monitoring
|
Not necessary for short procedural use |
|
Resumption
|
May resume breastfeeding once mother is fully conscious and alert |
ELDERLY
- Recommended starting dose: 0.1–0.15 mg/kg (lower end of range); consider 0.1 mg/kg in frail patients
- Titration: May have slower onset due to reduced cardiac output and perfusion
- Additional risks: Increased sensitivity possible; delayed recovery in presence of hypothermia or organ dysfunction
- Monitoring: Mandatory TOF monitoring; ensure complete recovery (TOF ratio ≥0.9) before extubation
MAJOR DRUG INTERACTIONS
| Interacting Drug | Effect | Management |
|
Aminoglycosides (gentamicin, amikacin, tobramycin)
|
Potentiation of neuromuscular blockade; prolonged paralysis | Avoid if possible; reduce cisatracurium dose; monitor closely |
|
Magnesium sulphate
|
Significant enhancement of blockade via presynaptic and postsynaptic mechanisms | Reduce dose substantially; critical in pre-eclampsia/eclampsia |
|
Succinylcholine
|
Unpredictable prolonged or enhanced blockade when used sequentially | Do not administer concurrently; allow recovery from succinylcholine before cisatracurium |
|
Inhalational anaesthetics (isoflurane, sevoflurane, desflurane)
|
Potentiate neuromuscular blockade | Reduce cisatracurium dose by 20–30% during inhalational anaesthesia |
|
Clindamycin, Lincomycin
|
Potentiate neuromuscular blockade | Monitor closely; may require dose reduction |
MODERATE DRUG INTERACTIONS
| Interacting Drug | Effect | Management |
|
Phenytoin, Carbamazepine (chronic use)
|
Resistance to non-depolarising blockers; reduced efficacy | May require higher doses; titrate to effect |
|
Corticosteroids (chronic/prolonged use)
|
Increased risk of ICU-acquired weakness/myopathy when combined with prolonged neuromuscular blockade | Limit duration of paralysis; monitor for weakness |
|
Lithium
|
May prolong neuromuscular blockade | Monitor TOF closely |
|
Calcium channel blockers
|
May enhance duration of action | Monitor neuromuscular function |
|
Loop diuretics
|
Electrolyte shifts (hypokalaemia) may potentiate blockade | Correct electrolytes; monitor |
COMMON ADVERSE EFFECTS
- Transient hypotension (less common than with atracurium)
- Mild flushing
- Bradycardia (infrequent)
- Injection site reactions
- Prolonged neuromuscular blockade (dose-dependent)
SERIOUS ADVERSE EFFECTS
- Anaphylaxis/Anaphylactoid reactions — rare but potentially fatal; immediate discontinuation and resuscitation required
- Prolonged paralysis — requiring extended mechanical ventilation
- Respiratory arrest — if ventilatory support inadequate
- ICU-acquired weakness/Critical illness myopathy — with prolonged use (>48–72 hours), especially when combined with corticosteroids
MONITORING REQUIREMENTS
| Timing | Parameters |
|
Baseline
|
Neuromuscular function (TOF if possible); electrolytes; cardiovascular status; allergy history |
|
During use
|
Continuous neuromuscular monitoring (TOF/peripheral nerve stimulator) every 15–30 minutes during procedures; BP; SpO₂; ETCO₂; ECG |
|
Before extubation
|
Ensure TOF ratio ≥0.9; clinical assessment (sustained head lift ≥5 seconds, adequate grip strength, vital capacity) |
|
Long-term ICU use
|
TOF monitoring every 4–6 hours; daily drug holidays to assess spontaneous movement; monitor for signs of ICU-acquired weakness |
BRANDS AVAILABLE IN INDIA
- Nimbex (Aspen/GSK)
- Cisatech
- Cistron
- Ciscure
Note: No fixed-dose combinations available
PRICE RANGE (INR)
| Formulation | Approximate Price |
| Cisatracurium 2 mg/mL (5 mL = 10 mg) | ₹350–₹650 per vial |
| Cisatracurium 10 mg/mL (5 mL = 50 mg) | ₹750–₹1200 per vial |
- Not under NPPA/NLEM price control
- Significantly costlier than atracurium
- Lower institutional pricing may be available at tertiary centres
CLINICAL PEARLS
- Preferred agent in renal/hepatic impairment — Hofmann elimination is completely organ-independent; no dose adjustment needed regardless of organ function
- Minimal histamine release — significantly less hypotension and bronchospasm compared to atracurium; preferred in cardiovascular instability or reactive airway disease
- No cumulative effect — predictable recovery profile even with repeated dosing or prolonged infusion; ideal for ICU use
- Costlier but cleaner profile — higher cost justified in high-risk patients where haemodynamic stability is paramount
- Always use neuromuscular monitoring — TOF monitoring is essential; clinical assessment alone is inadequate to prevent residual blockade
- ICU-acquired weakness risk — limit duration of infusion; daily interruption mandatory; avoid prolonged concurrent corticosteroid use when possible
TAGS
cisatracurium; neuromuscular blocking agent; NMBA; benzylisoquinolinium; anaesthesia; intubation; muscle relaxant; ICU paralysis; renal-safe; hepatic-safe; Hofmann elimination; TOF monitoring; Schedule H
VERSION
RxIndia v1.0 — 03 Feb 2026
REFERENCES
- CDSCO-approved prescribing information
- Indian Pharmacopoeia
- AIIMS Anaesthesia protocols
- API Textbook of Medicine
- Indian Society of Critical Care Medicine (ISCCM) protocols
- Goodman & Gilman’s Pharmacological Basis of Therapeutics
- Harrison’s Principles of Internal Medicine
- ACURASYS trial (for off-label ARDS use)
⚖️
Clinical Responsibility
This platform is designed strictly for healthcare professionals. Data provided is synthesized from authoritative pharmacological sources and clinical registries. Do not use for consumer medical decisions. Always verify critical dosing and contraindications with official institutional protocols and peer-reviewed journals.
Content Feedback
Is this information helpful?
Help us improve our clinical database for the medical community.